Aignostics

Aignostics released HETA Clinical, a family of pan-cancer AI products spanning the pathology workflow, with four initial products measuring slide quality, tumor presence, mitotic counts and tumor cellularity. These assessments are usually made by eye, which is time-consuming and varies between readers; pathologists the company spoke with at academic medical centers and precision medicine labs estimate that 10 to 20 percent of molecular tests fail because tissue lacks enough tumor. Built on the HETA platform, the products are positioned to confirm sufficient tumor before molecular testing and help labs prioritize cases.

Aignostics released HETA Clinical, a family of pan-cancer AI products spanning the pathology workflow, with four initial products measuring slide quality, tumor presence, mitotic counts and tumor cellularity. These assessments are usually made by eye, which is time-consuming and varies between readers; pathologists the company spoke with at academic medical centers and precision medicine labs estimate that 10 to 20 percent of molecular tests fail because tissue lacks enough tumor. Built on the HETA platform, the products are positioned to confirm sufficient tumor before molecular testing and help labs prioritize cases.